“…
eumocystis is an opportunistic pulmonary pathogen particularly associated with HIV-infected patients. Several studies have demonstrated a significant association between the use of sulfa drugs for Pneumcystis pneumonia (PcP) prophylaxis and the presence of DHPS (dihydropteroate synthase) gene point mutations, mainly at position 55 and 57 in the enzyme active site [1,2]. Pneumocystis DHPS mutations have been reported to be increasing in several countries and this may be an emerging public health problem.
…”